Side reactions following ivermectin therapy in high density bancroftian microfilaraemics.
Identifieur interne : 004F69 ( PubMed/Checkpoint ); précédent : 004F68; suivant : 004F70Side reactions following ivermectin therapy in high density bancroftian microfilaraemics.
Auteurs : S K Kar [Inde] ; S. Patnaik ; V. Kumaraswami ; R S MurtySource :
- Acta tropica [ 0001-706X ] ; 1993.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Animaux, Facteurs temps, Filariose lymphatique (enzymologie), Filariose lymphatique (parasitologie), Filariose lymphatique (traitement médicamenteux), Fièvre (), Humains, Ivermectine (administration et posologie), Ivermectine (effets indésirables), Ivermectine (pharmacologie), Mâle, Méthode en double aveugle, Nausée (), Phosphatase alcaline (sang), Pneumopathie infectieuse (), Toux (), Wuchereria bancrofti ().
- MESH :
- administration et posologie : Ivermectine.
- effets indésirables : Ivermectine.
- enzymologie : Filariose lymphatique.
- parasitologie : Filariose lymphatique.
- pharmacologie : Ivermectine.
- sang : Phosphatase alcaline.
- traitement médicamenteux : Filariose lymphatique.
- Adolescent, Adulte, Animaux, Facteurs temps, Fièvre, Humains, Mâle, Méthode en double aveugle, Nausée, Pneumopathie infectieuse, Toux, Wuchereria bancrofti.
English descriptors
- KwdEn :
- Adolescent, Adult, Alkaline Phosphatase (blood), Animals, Cough (chemically induced), Double-Blind Method, Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (enzymology), Elephantiasis, Filarial (parasitology), Fever (chemically induced), Humans, Ivermectin (administration & dosage), Ivermectin (adverse effects), Ivermectin (pharmacology), Male, Nausea (chemically induced), Pneumonia (chemically induced), Time Factors, Wuchereria bancrofti (drug effects).
- MESH :
- chemical , administration & dosage : Ivermectin.
- chemical , adverse effects : Ivermectin.
- chemical , blood : Alkaline Phosphatase.
- chemically induced : Cough, Fever, Nausea, Pneumonia.
- drug effects : Wuchereria bancrofti.
- drug therapy : Elephantiasis, Filarial.
- enzymology : Elephantiasis, Filarial.
- parasitology : Elephantiasis, Filarial.
- chemical , pharmacology : Ivermectin.
- Adolescent, Adult, Animals, Double-Blind Method, Humans, Male, Time Factors.
Abstract
Side reactions following ivermectin treatment were evaluated in sixty males with high density bancroftian microfilaremia (GM 1388/ml). Following a single oral dose of ivermectin of different strengths (20, 50, 100 or 200 micrograms/kg), microfilariae clearance and side reactions were monitored in a double blind fashion. Microfilaria levels fell rapidly after ivermectin administration in all dosage groups and 98% of pretreatment microfilariae was cleared after 12 h of treatment. The rate of microfilaria (mf) clearance was slower with 20 micrograms/kg than with the highest dose (200 micrograms/kg) administered. Forty-six patients (77%) became amicrofilaraemic within 2 weeks of treatment. Side reactions were noted in 97% of cases. The most common reactions were fever, headache, weakness, myalgia and cough which appeared by 12 h and subsided by 72 h following treatment. The frequency and intensity of side reactions were related to pretreatment mf densities and were independent of the dose administered. Unusual side reactions were noted in a few patients with high density microfilaraemia. These included intense cough, shortness of breath, blood tinged mucoid expectoration associated with patchy pneumonitis of the lung. Itchy rashes, lymphatic nodules and raised alkaline phosphatase level were also observed in some patients. These side reactions were transient, self limiting and were not serious enough to warrant any treatment. These exaggerated unusual reactions were possibly due to allergic response of the susceptible host to rapid killing of large number of microfilariae.
PubMed: 7903135
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:7903135Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Side reactions following ivermectin therapy in high density bancroftian microfilaraemics.</title><author><name sortKey="Kar, S K" sort="Kar, S K" uniqKey="Kar S" first="S K" last="Kar">S K Kar</name><affiliation wicri:level="1"><nlm:affiliation>Regional Medical Research Centre, Bhubaneswar, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Regional Medical Research Centre, Bhubaneswar</wicri:regionArea><wicri:noRegion>Bhubaneswar</wicri:noRegion></affiliation></author><author><name sortKey="Patnaik, S" sort="Patnaik, S" uniqKey="Patnaik S" first="S" last="Patnaik">S. Patnaik</name></author><author><name sortKey="Kumaraswami, V" sort="Kumaraswami, V" uniqKey="Kumaraswami V" first="V" last="Kumaraswami">V. Kumaraswami</name></author><author><name sortKey="Murty, R S" sort="Murty, R S" uniqKey="Murty R" first="R S" last="Murty">R S Murty</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1993">1993</date><idno type="RBID">pubmed:7903135</idno><idno type="pmid">7903135</idno><idno type="wicri:Area/PubMed/Corpus">005683</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005683</idno><idno type="wicri:Area/PubMed/Curation">005683</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">005683</idno><idno type="wicri:Area/PubMed/Checkpoint">005683</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">005683</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Side reactions following ivermectin therapy in high density bancroftian microfilaraemics.</title><author><name sortKey="Kar, S K" sort="Kar, S K" uniqKey="Kar S" first="S K" last="Kar">S K Kar</name><affiliation wicri:level="1"><nlm:affiliation>Regional Medical Research Centre, Bhubaneswar, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Regional Medical Research Centre, Bhubaneswar</wicri:regionArea><wicri:noRegion>Bhubaneswar</wicri:noRegion></affiliation></author><author><name sortKey="Patnaik, S" sort="Patnaik, S" uniqKey="Patnaik S" first="S" last="Patnaik">S. Patnaik</name></author><author><name sortKey="Kumaraswami, V" sort="Kumaraswami, V" uniqKey="Kumaraswami V" first="V" last="Kumaraswami">V. Kumaraswami</name></author><author><name sortKey="Murty, R S" sort="Murty, R S" uniqKey="Murty R" first="R S" last="Murty">R S Murty</name></author></analytic><series><title level="j">Acta tropica</title><idno type="ISSN">0001-706X</idno><imprint><date when="1993" type="published">1993</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Alkaline Phosphatase (blood)</term><term>Animals</term><term>Cough (chemically induced)</term><term>Double-Blind Method</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (enzymology)</term><term>Elephantiasis, Filarial (parasitology)</term><term>Fever (chemically induced)</term><term>Humans</term><term>Ivermectin (administration & dosage)</term><term>Ivermectin (adverse effects)</term><term>Ivermectin (pharmacology)</term><term>Male</term><term>Nausea (chemically induced)</term><term>Pneumonia (chemically induced)</term><term>Time Factors</term><term>Wuchereria bancrofti (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Animaux</term><term>Facteurs temps</term><term>Filariose lymphatique (enzymologie)</term><term>Filariose lymphatique (parasitologie)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Fièvre ()</term><term>Humains</term><term>Ivermectine (administration et posologie)</term><term>Ivermectine (effets indésirables)</term><term>Ivermectine (pharmacologie)</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Nausée ()</term><term>Phosphatase alcaline (sang)</term><term>Pneumopathie infectieuse ()</term><term>Toux ()</term><term>Wuchereria bancrofti ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Alkaline Phosphatase</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Cough</term><term>Fever</term><term>Nausea</term><term>Pneumonia</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="parasitologie" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="parasitology" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Ivermectine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Phosphatase alcaline</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Animals</term><term>Double-Blind Method</term><term>Humans</term><term>Male</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Animaux</term><term>Facteurs temps</term><term>Fièvre</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Nausée</term><term>Pneumopathie infectieuse</term><term>Toux</term><term>Wuchereria bancrofti</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Side reactions following ivermectin treatment were evaluated in sixty males with high density bancroftian microfilaremia (GM 1388/ml). Following a single oral dose of ivermectin of different strengths (20, 50, 100 or 200 micrograms/kg), microfilariae clearance and side reactions were monitored in a double blind fashion. Microfilaria levels fell rapidly after ivermectin administration in all dosage groups and 98% of pretreatment microfilariae was cleared after 12 h of treatment. The rate of microfilaria (mf) clearance was slower with 20 micrograms/kg than with the highest dose (200 micrograms/kg) administered. Forty-six patients (77%) became amicrofilaraemic within 2 weeks of treatment. Side reactions were noted in 97% of cases. The most common reactions were fever, headache, weakness, myalgia and cough which appeared by 12 h and subsided by 72 h following treatment. The frequency and intensity of side reactions were related to pretreatment mf densities and were independent of the dose administered. Unusual side reactions were noted in a few patients with high density microfilaraemia. These included intense cough, shortness of breath, blood tinged mucoid expectoration associated with patchy pneumonitis of the lung. Itchy rashes, lymphatic nodules and raised alkaline phosphatase level were also observed in some patients. These side reactions were transient, self limiting and were not serious enough to warrant any treatment. These exaggerated unusual reactions were possibly due to allergic response of the susceptible host to rapid killing of large number of microfilariae.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7903135</PMID><DateCreated><Year>1994</Year><Month>01</Month><Day>19</Day></DateCreated><DateCompleted><Year>1994</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-706X</ISSN><JournalIssue CitedMedium="Print"><Volume>55</Volume><Issue>1-2</Issue><PubDate><Year>1993</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Acta tropica</Title><ISOAbbreviation>Acta Trop.</ISOAbbreviation></Journal><ArticleTitle>Side reactions following ivermectin therapy in high density bancroftian microfilaraemics.</ArticleTitle><Pagination><MedlinePgn>21-31</MedlinePgn></Pagination><Abstract><AbstractText>Side reactions following ivermectin treatment were evaluated in sixty males with high density bancroftian microfilaremia (GM 1388/ml). Following a single oral dose of ivermectin of different strengths (20, 50, 100 or 200 micrograms/kg), microfilariae clearance and side reactions were monitored in a double blind fashion. Microfilaria levels fell rapidly after ivermectin administration in all dosage groups and 98% of pretreatment microfilariae was cleared after 12 h of treatment. The rate of microfilaria (mf) clearance was slower with 20 micrograms/kg than with the highest dose (200 micrograms/kg) administered. Forty-six patients (77%) became amicrofilaraemic within 2 weeks of treatment. Side reactions were noted in 97% of cases. The most common reactions were fever, headache, weakness, myalgia and cough which appeared by 12 h and subsided by 72 h following treatment. The frequency and intensity of side reactions were related to pretreatment mf densities and were independent of the dose administered. Unusual side reactions were noted in a few patients with high density microfilaraemia. These included intense cough, shortness of breath, blood tinged mucoid expectoration associated with patchy pneumonitis of the lung. Itchy rashes, lymphatic nodules and raised alkaline phosphatase level were also observed in some patients. These side reactions were transient, self limiting and were not serious enough to warrant any treatment. These exaggerated unusual reactions were possibly due to allergic response of the susceptible host to rapid killing of large number of microfilariae.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kar</LastName><ForeName>S K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Regional Medical Research Centre, Bhubaneswar, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patnaik</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kumaraswami</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Murty</LastName><ForeName>R S</ForeName><Initials>RS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Acta Trop</MedlineTA><NlmUniqueID>0370374</NlmUniqueID><ISSNLinking>0001-706X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>70288-86-7</RegistryNumber><NameOfSubstance UI="D007559">Ivermectin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.1</RegistryNumber><NameOfSubstance UI="D000469">Alkaline Phosphatase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000469" MajorTopicYN="N">Alkaline Phosphatase</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003371" MajorTopicYN="N">Cough</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000469" MajorTopicYN="N">parasitology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005334" MajorTopicYN="N">Fever</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007559" MajorTopicYN="N">Ivermectin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009325" MajorTopicYN="N">Nausea</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011014" MajorTopicYN="N">Pneumonia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014958" MajorTopicYN="N">Wuchereria bancrofti</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7903135</ArticleId><ArticleId IdType="pii">0001-706X(93)90045-D</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Inde</li></country></list><tree><noCountry><name sortKey="Kumaraswami, V" sort="Kumaraswami, V" uniqKey="Kumaraswami V" first="V" last="Kumaraswami">V. Kumaraswami</name><name sortKey="Murty, R S" sort="Murty, R S" uniqKey="Murty R" first="R S" last="Murty">R S Murty</name><name sortKey="Patnaik, S" sort="Patnaik, S" uniqKey="Patnaik S" first="S" last="Patnaik">S. Patnaik</name></noCountry><country name="Inde"><noRegion><name sortKey="Kar, S K" sort="Kar, S K" uniqKey="Kar S" first="S K" last="Kar">S K Kar</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004F69 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 004F69 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:7903135
|texte= Side reactions following ivermectin therapy in high density bancroftian microfilaraemics.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:7903135" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |